German HTA Body Slams Lack Of 'Real Innovation'
Executive Summary
Too many new drugs have the same mechanism of action, says Germany’s health technology appraisal institute, IQWiG.
You may also be interested in...
Industry Demands Rethink Of German HTA Data Requirements
The pharmaceutical industry is calling for more flexible evidence requirements for health technology assessments in Germany after the country’s HTA body, IQWiG, claimed that too many new products entering the market lack additional benefit.
European Commission HTA Proposals Should Mandate Comparative Trials, Says Germany
Pharmaceutical companies should be obliged to carry out comparative trials, according to analysis from Germany’s Institute For Quality and Efficiency in Healthcare, IQWiG.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.